---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-005511"
form_type: "8-K"
ticker: "DNA"
cik: "0001830214"
company_name: "Ginkgo Bioworks Holdings, Inc."
filed_at: "2023-03-01T23:59:59+00:00"
generated_at: "2026-06-18T18:45:42.045546+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Ginkgo Bioworks reports 2022 revenue up 52% to $478M; guides 2023 total revenue at least $275M

## Summary
- Full year 2022 total revenue $478M (+52% YoY); Foundry $144M (+27%), Biosecurity $334M (+66%).
- Adjusted EBITDA loss widened to $(173)M in 2022 from $(106)M in 2021; operating loss $(2.2)B includes $1.9B stock comp.
- 2023 guidance: 100 new Cell Programs; total revenue at least $275M (Foundry ≥$175M, Biosecurity ≥$100M).
- Cash and equivalents over $1.3B; filing extension for 10-K due to becoming large accelerated filer.
- Added 59 new Cell Programs in 2022 (90% growth); downstream milestone potential added over $2.0B.

## SEC filing metadata
- accession: 0000950170-23-005511
- form_type: 8-K
- ticker: DNA
- cik: 0001830214
- company_name: Ginkgo Bioworks Holdings, Inc.
- filed_at: 2023-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1830214/000095017023005511/0000950170-23-005511-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1830214/000095017023005511/dna-20230301.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-005511
- JSON: https://secwatch.observer/filing/0000950170-23-005511.json
- Plain text: https://secwatch.observer/filing/0000950170-23-005511.txt

## Key facts
- Earnings Releases
  Ginkgo Bioworks Holdings, Inc. reported fourth quarter 2022 and year ended December 31, 2022 results: revenue $478 million. Guidance reaffirmed.
  - Period: fourth quarter 2022 and year ended December 31, 2022
  - Revenue: $478 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Ginkgo Bioworks Reports Fourth Quarter and Full Year 2022 Financial Results $478 million of total revenue in 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1830214/000095017023005511/0000950170-23-005511-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.